Focal therapy use remains uncommon in nonmetastatic prostate cancer
For patients with nonmetastatic prostate cancer, focal therapy use has remained uncommon across risk groups, and its use was defined as inappropriate in about half of recipients, according to a research letter published online Aug. 13 in the JAMA.
A study published in JAMA reveals that focal therapy use remains uncommon in nonmetastatic prostate cancer patients, with only 1.3% of the 1.18 million U.S. patients included in the research receiving this treatment. While focal therapy use did increase modestly in favorable intermediate-risk disease, it declined in unfavorable intermediate-, high-, and very high-risk disease categories.
This shift in usage highlights the need for evidence-based adoption of treatments that match patients' likelihood of benefiting from the therapy.
Brief written by urgent.news from Medical Xpress's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
